{
  "id": 4638398,
  "title": "H.C. Wainwright reiterates Gain Therapeutics stock rating at buy",
  "url": "https://urgent.news/2026/08/31/h-c-wainwright-reiterates-gain-therapeutics-stock-rating-at-buy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T11:42:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-gain-therapeutics-stock-rating-at-buy-93CH-4882611"
  },
  "original_language": "en",
  "account": null,
  "summary": "H.C. Wainwright has reaffirmed its Buy rating for Gain Therapeutics (NASDAQ:GANX) shares, maintaining a price target of $8.00. The stock is currently trading at $1.77, down 45% year-to-date, but analysts believe the company is undervalued at its current price. Gain Therapeutics received FDA authorization for its Investigational New Drug application for lead candidate GT-02287, which will initiate a Phase 2 clinical assessment for Parkinson's disease in the U.S. The company's Phase 1 trials in Australia showed promising biomarker and clinical evidence, along with favorable safety and tolerability.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright raises Brainsway stock price target on new data",
        "url": "https://urgent.news/2026/08/31/h-c-wainwright-raises-brainsway-stock-price-target-on-new-data",
        "published": "2026-08-31T11:42:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}